1. Home
  2. HURA vs ELLO Comparison

HURA vs ELLO Comparison

Compare HURA & ELLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • ELLO
  • Stock Information
  • Founded
  • HURA 2009
  • ELLO 1987
  • Country
  • HURA United States
  • ELLO Israel
  • Employees
  • HURA N/A
  • ELLO N/A
  • Industry
  • HURA
  • ELLO Electric Utilities: Central
  • Sector
  • HURA
  • ELLO Utilities
  • Exchange
  • HURA Nasdaq
  • ELLO Nasdaq
  • Market Cap
  • HURA 246.9M
  • ELLO 208.2M
  • IPO Year
  • HURA N/A
  • ELLO 1995
  • Fundamental
  • Price
  • HURA $4.76
  • ELLO $16.79
  • Analyst Decision
  • HURA Strong Buy
  • ELLO
  • Analyst Count
  • HURA 1
  • ELLO 0
  • Target Price
  • HURA $11.00
  • ELLO N/A
  • AVG Volume (30 Days)
  • HURA 262.4K
  • ELLO 5.4K
  • Earning Date
  • HURA 02-15-2025
  • ELLO 12-30-2024
  • Dividend Yield
  • HURA N/A
  • ELLO N/A
  • EPS Growth
  • HURA N/A
  • ELLO N/A
  • EPS
  • HURA N/A
  • ELLO N/A
  • Revenue
  • HURA N/A
  • ELLO $44,850,546.00
  • Revenue This Year
  • HURA N/A
  • ELLO N/A
  • Revenue Next Year
  • HURA N/A
  • ELLO N/A
  • P/E Ratio
  • HURA N/A
  • ELLO N/A
  • Revenue Growth
  • HURA N/A
  • ELLO N/A
  • 52 Week Low
  • HURA $2.84
  • ELLO $11.08
  • 52 Week High
  • HURA $14.60
  • ELLO $20.81
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • ELLO 57.39
  • Support Level
  • HURA N/A
  • ELLO $15.86
  • Resistance Level
  • HURA N/A
  • ELLO $20.81
  • Average True Range (ATR)
  • HURA 0.00
  • ELLO 0.93
  • MACD
  • HURA 0.00
  • ELLO 0.02
  • Stochastic Oscillator
  • HURA 0.00
  • ELLO 34.21

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About ELLO Ellomay Capital Ltd (Israel)

Ellomay Capital Ltd is focused on the utility sector. It is an Israeli public company, which focuses its business in the energy and infrastructure sectors. The company's operating segment includes Photovoltaic power plants (PV Plants); Dorad Energy Ltd. (Dorad); Groen Gas Goor B.V. and a Pumped storage hydro power plant (Manara). It generates maximum revenue from the Dorad segment. Geographically, it derives a majority of its revenue from Spain.

Share on Social Networks: